Abstract
Purpose The risk of developing age-related macular degeneration(AMD) is influenced by genetic background. In 2016, International AMD Genomics Consortium(IAMDGC) identified 52 risk variants in 34 loci, and a polygenic risk score(PRS) based on these variants was associated with AMD. The Israeli population has a unique genetic composition: Ashkenazi Jewish(AJ), Jewish non-Ashkenazi, and Arab sub-populations. We aimed to perform a genome-wide association study(GWAS) for AMD in Israel, and to evaluate PRSs for AMD.
Methods For our discovery set, we recruited 403 AMD patients and 256 controls at Hadassah Medical Center. We genotyped all individuals via custom exome chip. We imputed non-typed variants using cosmopolitan and AJ reference panels. We recruited additional 155 cases and 69 controls for validation. To evaluate predictive power of PRSs for AMD, we used IAMDGC summary statistics excluding our study and developed PRSs via either clumping/thresholding or LDpred2.
Results In our discovery set, 31/34 loci previously reported by the IAMDGC were AMD associated with P<0.05. Of those, all effects were directionally consistent with the IAMDGC and 11 loci had a p-value under Bonferroni-corrected threshold(0.05/34=0.0015). At a threshold of 5x10-5, we discovered four suggestive associations in FAM189A1, IGDCC4, C7orf50, and CNTNAP4. However, only the FAM189A1 variant was AMD associated in the replication cohort after Bonferroni-correction. A prediction model including LDpred2-based PRS and other covariates had an AUC of 0.82(95%CI:0.79-0.85) and performed better than a covariates-only model(P=5.1x10-9).
Conclusions Previously reported AMD-associated loci were nominally associated with AMD in Israel. A PRS developed based on a large international study is predictive in Israeli populations.
Competing Interest Statement
Conflict of Interest Statement S.C. is a paid consultant to MyHeritage. All other authors have no competing interests to disclose.
Funding Statement
This work was supported by a grants from the Israel Science Foundation: 3485/19 to I.C. and S.C. The contribution of the International AMD Genomics Consortium (IAMDGC) was supported by a grant from NIH (R01 EY022310). Genotyping was supported by a contract (HHSN2682012000081) to the Center for Inherited Disease Research. MG is supported by a grant from the Bright Focus Foundation (M2021006F).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional ethics committee of Hadassah Medical Center. All subjects signed informed consent forms that adhered to the tenets of the declaration of Helsinki. The IAMDGC study participants were previously ascertained by IAMDGC cohorts as described in Fritsche et al, 2016, Nature Genetics. All participants provided informed consent, and the study was approved by institutional review boards as previously described.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This work was supported by a grant from the Israel Science Foundation: 3485/19 to I.C. and S.C. The contribution of the International AMD Genomics Consortium (IAMDGC) was supported by a grant from NIH (R01 EY022310). Genotyping was supported by a contract (HHSN2682012000081) to the Center for Inherited Disease Research. MG is supported by a grant from the Bright Focus Foundation (M2021006F).
Data Availability
The full IAMDGC dataset values can be accessed at: http://amdgenetics.org/ including the entire IAMDGC and the Jerusalem dataset specifically. In addition, the GWAS summary statistics and code utilized in this manuscript can be found by contacting the corresponding author via reasonable request. The Related Manuscript Variant supplementary file contains all nomenclature for HGVS for all variants.